Preliminary pharmacokinetic (PK) data from OXPzeroTM Ibuprofen demonstrates that the product has been optimised to provide immediate release and complete drug absorption as well as a taste masked benefit. OXPzeroTM Ibuprofen has now progressed to the second phase of its pilot clinical trial, a comparative endoscopy trial to demonstrate reduced gastro-intestinal irritation, highlighting the group’s confidence in the product. Headline endoscopy data is expected in Q4 2015 along with complete PK da ....
